Since IRF1 unaffected the OS of liver cancer patients (Fig. 4L) and c-Src acts as an effector in the METTL3/IRF1/c-Src axis, we further overexpressed c-Src in sh-METTL3 Huh7 and siMETTL2 HepG2 cells, respectively, to confirm the oncogenic role of METTL3/IRF1/c-Src axis in liver cancer cell proliferation. Here, SRC is linked to liver cancer.